Update shared on24 Sep 2025
Fair value Decreased 2.72%Globus Medical’s price target was revised downward as analysts cited muted year-over-year performance in the Enabling Technology segment and less-than-expected robotic sales growth, despite an EPS beat and quarter-to-quarter recovery, resulting in a new fair value of $80.30.
Analyst Commentary
- Q2 sales were in line with the company's pre-announcement.
- EPS exceeded consensus expectations by $0.11.
- Enabling Technology segment sales rebounded quarter-to-quarter but remained down year-over-year.
- Analysts were hoping for stronger robotic sales growth.
- The positive quarter-to-quarter recovery in Enabling Tech was seen as encouraging.
What's in the News
- The company completed a share buyback of 411,000 shares (0.3% of outstanding) for $24.99 million under the May 2025 authorization.
- Full-year 2025 revenue guidance reaffirmed at $2.80–$2.90 billion.
- Daniel T. Scavilla resigned as CEO; Keith W. Pfeil was appointed CEO. Pfeil brings extensive experience as former COO and CFO, with a background in operations, finance, and business development.
- Kyle Kline appointed Chief Financial Officer, bringing internal continuity and accounting leadership, following roles as SVP of Finance and experience at Deloitte.
- Expanded Excelsius navigation capabilities and launched next-generation oscillating system DuraPro and navigated high-speed drill system Verzera, further integrating with the ExcelsiusGPS and ExcelsiusHub platforms to enhance procedural workflows and surgeon confidence.
Valuation Changes
Summary of Valuation Changes for Globus Medical
- The Consensus Analyst Price Target has fallen slightly from $82.55 to $80.30.
- The Future P/E for Globus Medical has fallen slightly from 24.88x to 24.20x.
- The Consensus Revenue Growth forecasts for Globus Medical remained effectively unchanged, at 9.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.